Pemigatinib is primarily used for patients with cholangiocarcinoma who have specific genetic alterations in the FGFR2 gene. Before starting treatment, patients typically undergo genetic testing to identify these alterations. The drug is also being investigated for its efficacy in other FGFR-altered cancers, including urothelial carcinoma and glioblastoma.
